Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02170337 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps
A Phase 1 study of Chronic Rhinosinusitis With Nasal Polyps, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
- 4
- Study locations
NCT02170337 is a Phase 1 study of Chronic Rhinosinusitis With Nasal Polyps that has completed, run by Amgen. The registered enrollment target is 41 participants, below the 139-participant average among 11 other Chronic Rhinosinusitis With Nasal Polyps trials with a reported enrollment target (71% lower). The trial reports 4 study locations across 4 states.
The verdict
NCT02170337, a Phase 1 study of Chronic Rhinosinusitis With Nasal Polyps, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
- 4
- Study locations
Study Summary
A randomized, double-blind, ascending multiple dose study in healthy volunteers and subjects with chronic rhinosinusitis with nasal polyps
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AMG 282
Study Locations (4)
California
- Research Site - Santa Monica
Colorado
- Research Site - Aurora
Florida
- Research Site - South Miami
Texas
- Research Site - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2014-07 |
| Est. Completion | 2016-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02170337
The ClinicalTrials.gov registry entry for NCT02170337 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 139-participant average among 11 other Chronic Rhinosinusitis With Nasal Polyps trials with a reported enrollment target (71% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Rhinosinusitis With Nasal Polyps appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02170337 reports 4 study locations spanning 4 distinct geographic areas - top geographies include California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT02170337 about?
NCT02170337 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AMG 282 in Healthy Subjects and Subjects With Chronic Rhinosinusitis With Nasal Polyps". A randomized, double-blind, ascending multiple dose study in healthy volunteers and subjects with chronic rhinosinusitis with nasal polyps
What is the current status of trial NCT02170337?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2014-07. Estimated completion is 2016-05.
What conditions does trial NCT02170337 study?
This clinical trial studies the following conditions: Chronic Rhinosinusitis With Nasal Polyps.
What interventions are being tested in trial NCT02170337?
The interventions under investigation include: Placebo (DRUG), AMG 282 (DRUG).
Who is sponsoring clinical trial NCT02170337?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02170337 being conducted?
This trial has 4 study locations across California, Colorado, Florida, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Rhinosinusitis With Nasal Polyps
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
RECRUITING · Phase 3
-
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study
RECRUITING · Phase 2
-
The Role of IL5 in Epithelial Cell Integrity
RECRUITING · Early Phase 1
-
A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab
RECRUITING · Phase 3
-
3D Printing to Improve Nasal Irrigation Outcome
RECRUITING · NA
-
Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.